Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
NEW YORK, April 22, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources, development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company's programs include: COMETRIQ, Cobimetinib Collaboration, and Other Collaborations. The company's collaborations include partnerships with Merck, Bristol-Myers Squibb Company and others.
For a more detailed research report with analyst comments and recommendation on Exelixis, Inc. please follow the link. There is no cost obligation required to view analyst brief:
http://bit.ly/--EXEL--AnalystReport
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Robert Borowski, research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Share this article